一名分析師周五說Mylan因為提高藥價而可能面臨價格審查，結果Mylan股價下降6%，看看今天中國股市，這點降不是痛。Myan也挺敢干，24個產品藥價至少提高20%，其中7個產品提高100%以上。中國藥企只有羨慕的份兒，這點看出美國政府真不行。Mylan發言人說分析師的說法有缺陷，我們銷售1400個產品，只有24個產品漲價，你就唧唧歪歪。拉黑你。
美國政府的確開始審查開始漲價的四個藥企。
原文如下
Analyst suggests Mylan could face price scrutiny
(Ref: Bloomberg, The Street, Investor's Business Daily, CNBC)
June 10th, 2016
By: Joe Barber
An analyst at Wells Fargo hinted on Friday that Mylan could become the next drugmaker to face scrutiny over its pricing practices, sending shares in the company down as much as 6 percent. Analyst David Maris noted that the company has implemented price hikes of at least 20 percent on 24 products, including hikes of more than 100 percent for seven products, within the last six months. "Given the regulatory environment, these pricing actions could bring greater scrutiny and headline risk," Maris stated.
Maris specifically cited a 542-percent price increase for the therapy ursodiol, a 444 percent increase for metoclopramide and a hike of 400 percent for dicyclomine. The analyst also noted a 56-percent price increase for tolterodine, while he said the drugmaker increased the price of Epi-Pen by 15 percent last month.
"We believe that given the regulatory environment, these pricing actions could bring greater regulatory scrutiny and headline risk," Maris suggested, adding "additionally, we wonder if aggressive price increases are being used to make EPS targets or to offset disappointing sales in other areas."
Commenting on the news, Mylan spokeswoman Nina Devlin argued that the company's business model "is not today, nor has it ever been, premised on price hikes," continuing "a flawed analysis focusing on a small number of products out of the more than 1400 products Mylan sells globally and the approximatively 600 products we sell in North America is simply self-serving and misleading to investors."
The news comes after members of the US Congress accused four drugmakers, including Valeant Pharmaceuticals and Turing Pharmaceuticals, on focusing on profit as opposed to helping patients when enacting price increases. The US Senate Special Committee on Aging previously asked the drugmakers to justify large price increases on off-patent therapies, while, former Valeant CEO Michael Pearson acknowledged that the drugmaker was too aggressive in implementing price hikes for older products.
